Both agents target the PD‐1/PD‐L1 pathway; however, their mechanisms differ—avelumab blocks PD‐L1 on tumor cells, indirectly reactivating T‐cells, while pembrolizumab directly inhibits PD‐1 receptors on T‐cells, preventing their inactivation [77]. Here, CD274 is linked to neoplasm.